FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT What Grounded Boeings and FDA Have in Common
03/15/2019
 
 
TXT FDA Steps to Modernize Clinical Trials
03/14/2019
 
 
TXT NCI Head Sharpless Appointed FDA Acting Commissioner
03/12/2019
 
 
TXT CDRH Reorganizes for Total Product Life Cycle
03/13/2019
 
 
TXT Trial Enrichment Strategies Guidance
03/14/2019
 
 
TXT FDA Finds Increased Mortality with Paclitaxel Devices
03/15/2019
 
 
TXT 5 Cancer Trial Eligibility Guidances
03/12/2019
 
 
TXT CGMP Violations at Hospira Healthcare India
03/12/2019
 
 
TXT Covidien Settling False Claims Act Case for $17 Million
03/12/2019
 
 
TXT Risk-Based Investigation Guidance
03/14/2019
 
 
TXT Promoting Unapproved Drugs is OPDP Focus: Analysis
03/13/2019
 
 
TXT Guidance on Devices with Animal Source Materials
03/14/2019
 
 
TXT Court Denies Summary Judgment in Teva Whistleblower Case
03/13/2019
 
 
TXT FDA Blocks PMA Approvals from Integra Subsidiary
03/11/2019
 
 
TXT Since Our Last Issue ...
03/17/2019
 
 
TXT Latest Federal Register Notices
03/17/2019
 
 
TXT Product Approval Summaries
03/17/2019
 
 
TXT Advisory Panel to Mull Device Metal Hypersensitivity
03/15/2019
 
 
TXT Spectrum BLA for Rolontis Withdrawn After FDA Request
03/15/2019
 
 
TXT Guilty Pleas in Fraudulent Supplement Sales Scheme
03/14/2019
 
 
TXT 2 EIRs Issued to Pharmaceutics International
03/14/2019
 
 
TXT Hematologic Disorder Drug Development Guidance
03/14/2019
 
 
TXT 10 Observations on Genetech FDA-483
03/13/2019
 
 
TXT 4 Observations in Immunomedics FDA-483
03/13/2019
 
 
TXT Software Precertification Program Comments
03/12/2019
 
 
TXT Guardian Pharmacy Services Consent Decree
03/12/2019
 
 
TXT Latest FDA Warning Letters
03/12/2019
 
 
TXT Biocon FDA-483
03/12/2019
 
 
TXT FDA Qualifies 1st Biomarker Test Tool Type
03/12/2019
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving